

Astellas Announces Personnel Changes and Organizational Changes

Tokyo, August 24, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the personnel changes and organizational changes as below.

1. Personnel Changes effective on October 1, 2017

| Name | New Title | Current Title |
|----------------------|--|---|
| Catherine J. Wertjes | Head of Ethics & Compliance (No change: only Japanese organization name will be changed) | Head of Ethics & Compliance |
| Hideki Yamanaka | Vice President, Ethics & Compliance, Japan and Asia Oceania | Vice President, Ethics & Compliance, Japan and East Asia |
| Emi Ito | Vice President, Sales Capability Development & Training, Japan Sales & Marketing | Senior Director, Product Marketing, Japan Sales & Marketing |
| Tomonobu Koizumi | Staff Executive Director, Innovation & Incubation Research Labs., DDR | Vice President, Regenerative Medicine Labs., DDR |
| Atsunori Kaibara | Staff Executive Director, Japan-Asia Clinical Pharmacology, Development | Senior Director, Japan-Asia Clinical Pharmacology, Development |

DDR: Drug Discovery Research

2. Organizational Changes effective on October 1, 2017

Regenerative Medicine Labs.

To further increase the productivity for regenerative medicine research, Regenerative Medicine Labs. will be reorganized and integrated into Astellas Institute for Regenerative Research (AIRM). AIRM will be a major function of regenerative medicine research in Astellas group. Astellas continues to pursue joint research and collaborations in Japan as ever.

Sales Capability Development & Training

The human resources functions (talent management, labor administration, compensation and benefit, diversity & inclusion, etc.) at Japan Sales & Marketing will be transferred to Human Resources and this department will focus on the training function specific to Japan Sales & Marketing. In accordance with this change, “Human Resources Development” will be renamed “Sales Capability Development & Training”.

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473